The Bleed Beyond Menopause: A Hidden Chapter in Women's Health - A Narrative Review

Postmenopausal bleeding (PMB), defined as any uterine bleeding occurring after 12 months of amenorrhea, remains a key clinical concern requiring thorough assessment. Although the majority of cases arise from benign conditions such as endometrial atrophy, polyps, or hormone-related effects, PMB can also be an early indicator of gynecologic malignancies, particularly endometrial and cervical cancers. The risk of malignancy increases with advancing age and is influenced by factors such as obesity, diabetes, hypertension, and prolonged exposure to unopposed estrogen. This narrative review discusses the diverse etiologies of PMB, outlines current diagnostic strategies, and reviews associated histopathological findings and management options. Transvaginal ultrasonography (TVUS) is the preferred initial modality, with endometrial thickness thresholds guiding further intervention. In cases where the endometrium measures ≥5 mm or presents with irregularities, additional evaluation through biopsy or hysteroscopy is warranted. Histologic patterns commonly include atrophic changes, polyps, hyperplasia, and, in a subset of patients, carcinoma. An interdisciplinary approach—integrating gynecologists, radiologists, pathologists, and clinical pharmacists—is essential to improve diagnostic accuracy and treatment outcomes. Clinical pharmacists contribute by reviewing medication profiles, managing hormonal therapies, and supporting adherence. In conclusion, PMB should never be dismissed as trivial. Early recognition, systematic evaluation, and coordinated care are critical to identifying underlying pathology and improving prognostic outcomes in postmenopausal women.